20May 2019

FORMULATION AND EVALUATION OF FLOATING MICROSPHERES OF FAMOTIDINE HYDROCHLORIDE.

  • Luqman college of pharmacy, Gulbarga, Karnataka.
  • Birat Medical College, Biratnagar, Nepal.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Controlled release gastric floating drug delivery system has a bulk density less than gastric fluids, so it remain buoyant in the stomach without affecting the gastric emptying rate for prolonged period of time. There by releasing the drug for prolonged period of time constantly to the upper part of the GIT and improves the bioavailability of drug with narrow absorption window. Famotidine is a histaminic drug that has been widely used in treating gastric and duodenal ulceration and also in zollinger elison syndrome and reflux oesophagitis. It works by reducing swelling and constricting blood vessels in the GIT passage, allowing you to get relief from gastritis easily. Floating microspheres are gastro-retentive drug delivery system. These microspheres are free flowing powders, gastric contents for prolonged time. Hence faster dissolution of dosage form results in faster absorption and onset of action. Floating microspheres are absorbed from mouth, pharynx and esophagus as the saliva passes down the stomach. In such cases the bioavailability is greater than those observed for conventional dosage form. Different polymers such as ethyl cellulose, sodium alginate were optimized with different concentration and varying the ratios in order to get the sustained release profile over a period of 24 hrs. All the formulations were evaluated for in-vitro buoyancy, entrapment efficiency and in-vitro drug release profile. The results revealed that the present buoyancy is more than 70% after 24 hrs. The mean particle size of microspheres was in the range of 102.33-420.53 ?m. In-vitro release of floating microspheres of Famotidine HCL was found to be in following order,H1>HE1>H2>HE4>E1>HE2>H3>HE3>HE5>E2>E3. H1 was found to be the best formulation among all other formulation prepared as it release Famotidine HCL 98.84 % in a sustained manner with constant fashion over extended period of time (after 24 hr).

  1. Yeole PG, Khan S, Patel VF. floating drug delivery systems: Need and Development. Ind. J. Pharm. Sci. 2005; 67(3): 265-272.
  2. Banker GS, Anderson NR. Tablets: The theory and practice of industrial pharmacy. 3rd. Bombay : Varghese Pub. House; s2003.
  3. Chein YW. Novel Drug Delivery Systems. 2nd ed. New York: Marcel Dekker. Inc.1992.
  4. Lee TW, Robinson JR. Remington: The Science and Practice of Pharmacy. 20th Pennsylvania: Mack Publishing Company; 2001.
  5. Aulton ME. Pharmaceutics: The Science of Dosage Form Design. 2nd Livingstone C. Elsevier science Ltd; 2002.
  6. Welling PG, Dobrinska M.Controlled drug delivery: Fundamentals and applications. 2nd ed. New York: Marcell Dekker Inc; 1987.
  7. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics a treatise. Reprint of 1st Delhi : Vallabh Prakashan; 2003.
  8. Anurag Sood, Ramesh Panchagnula. Design of controlled release delivery systems using a modified pharmacokinetic approach: a case study for drugs having a short elimination half-life and a narrow therapeutic index. International Journal of Pharmaceutics 2003; 261: 27?41.
  9. Vyas SP, Khar RK. Gastro-retentive system In: Controlled Drug Delivery System: Concept & Advances. 1st New Delhi:Vallabh Prakashan; 2002.
  10. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery system. A review. AAPS Pharm Sci Tech 2005; 6(3): 372-390.
  11. Chawla G, Gupta P, Koradia V, Bansal AK. Gastroretention A means to address regional variability in intestinal drug absorption.Pharmaceutical Technology 2003:50-68.
  12. Singh B, Ahuja N. Progress in Controlled and Novel Drug Delivery System. New Delhi: CBS Publishers and Distributors; 2004.
  13. Etyan, AK, Eran, L, Michel, F, Hoffman, A. Expandable gastroretentive dosage forms. J. Cont. Rel. 2003; 909: 143-162.
  14. Chatterjee CC. Human Physiology, Medical allied Agency, 11th2001
  15. Aspde TJ, Mason JDT, Jones NS, Lowe J, Skaugrud O, Illum L. Chitosan as a nasal delivery system: The effect of chitosan solutions on in vitro and in vivo mucociliary transport rates in human turbinates and volunteers. J Pharm Sci 1997; 86: 509-513.
  16. Garg S, Sharma S. Gastroretentive drug delivery systems. Business Brief Pharmatech 5th 2003: Available at: http://www.touchbriefings.com/cdps/cditem.cfm?NID-17&CID-5
  17. Singh BN, Kwon HK. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. Journal of Controlled Release 2000; 63:235?249.
  18. Amnon Hoffmana, David SA, Eran Lb, Sara EA, Eytan KA, Michael FA. Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. International Journal of Pharmaceutics 2004; 277: 141?153
  19. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive Dosage Forms: Overview and Special case of Helicobacter pylori. Journal of Controlled Release 2006; 111: 1-18
  20. AV Mayavanshi, SS Gajjar. Floating drug delivery systems to increase gastric retention of drugs: A Review. Research J. Pharm. and Tech. 2008; 1(4): 345-358.
  21. Fix JA, Cargill R, Engle E. Controlled gastric emptying III. Gastric residence time of a non-disintegrating geometric shape in human volunteers. Pharm Res 1993; 10: 1087-1089.
  22. Hilton AK, Deasai PB. Invitro and In vivo evaluation of an oral sustained release dosage form of Amoxycillin trihydrate. Int J Pharm 1992; 86:79- 88.
  23. Shivkumar HG, Vishakanta GD, PramodKumar TM. Formulation and evaluation of mucoadhesive drug delivery system for some anti-asthmatic drugs. IJPE 2004 Oct-Dec.; 38(4): 22-26
  24. Patel A, Ray S, Thakur RS. In vitro evaluation and optimization of controlled release floating delivery system of metformin hydrochloride. DARU 2006; 55: 277-285.
  25. K. singh, C.H. Borkhataria, Dr.N.R.Seth: Formulation and in-vitro evaluation of lansoprazole micropellets. Int. journal of pharmatech research oct-dec 2009(1);1530-1540
  26. Sato Y, Kawashima Y, Takeuchi H, Yamamoto H. in vivo evaluation of riboflavin-containing microballoons for floating controlled drug delivery system in healthy human volunteers. J Control Release 2003; 93(1): 39-47.
  27. Jain NK. Controlled and Novel Drug Delivery. 1st ed. New Delhi :CBS Publishers and Distributors; 2002.
  28. Swarbrick J, Boylan JC. Encyclopedia of Pharmaceutical Technology. 2ndUSA: Marcel Dekker Inc;2002.
  29. Stanley Davis. Formulation statergies for absorption windows. DDT 2005;10(4):249-257.
  30. Martin A, Swarbrick J, Cammarata A. Physical Pharmacy. 2nd ed. Bombay: Varghese Publishing Company; 1991.
  31. Carstensen JT. Pharmaceutics of solids and solids dosage forms. John Wiley and Sons. Newyork, 1976; 136-230.
  32. Salunke P, Rane B, Bakliwal S, Pawar S. Floating microcarriers of an antidiabetic drug: preparation and its in-vitro J.of Pharm. Sci. and Tech. 2010; 2(6): 230-240.
  33. Kumar R, Patil S, Patil MB, Patil SR, Paschapur MS. Isolation and evaluation of disintegrant properties of fenugreek seed mucilage. Int. J. of Pharm. Tech. Oct-Dec. 2009; 1(4): 982-996.

[Someshwar Tiwari, S. Satyanandam, M.A Saleem and Sushil Kumar sah. (2019); FORMULATION AND EVALUATION OF FLOATING MICROSPHERES OF FAMOTIDINE HYDROCHLORIDE. Int. J. of Adv. Res. 7 (May). 538-545] (ISSN 2320-5407). www.journalijar.com

Dr. Sushil Kumar Sah
Lecturer in Birat Medical College &Teaching Hospital Biratnagar, Nepal

DOI:

Article DOI: 10.21474/IJAR01/9070      
DOI URL: http://dx.doi.org/10.21474/IJAR01/9070

Download Full Paper

Download PDF No. of Downloads: 238 | No. of Views: 546